nature.com search

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Search
My Account Login

nature
search

advanced

where the list of authors contains where the title contains

Refine your results by…

volume

start page / article no.

Filters

Filter By:

Article type

Check one or more article types to show results from those article types only.

Research (6)

Journal

Check one or more journals to show results from those journals only.

British Journal of Cancer (2)
Scientific Reports (2)
Oncogene (1)
Oncogenesis (1)

Choose more journals

Subject Check one or more subjects to show results from those subjects only.

Targeted therapies (3)
Non-small-cell lung cancer (2)
Cancer (1)
Cancer genomics (1)
Cancer therapeutic resistance (1)

Date

Choose a date option to show results from those dates only.

Today
Last 7 days
Last 30 days
In the last year
Last 2 years
Last 5 years

Custom date range

Sort by Relevance

Choose a way to sort results.

Relevance
Date — most recent
Date — oldest first

Loading Filters

Showing 1–6 of 6 results

Loading Filters

Research | 10 December 2020
Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts
- Ryoji Kato
- , Koji Haratani
- , Hidetoshi Hayashi
- , Kazuko Sakai
- , Hitomi Sakai
- , Hisato Kawakami
- , Kaoru Tanaka
- , Masayuki Takeda
- , Kimio Yonesaka
- , Kazuto Nishio
- & Kazuhiko Nakagawa
British Journal of Cancer , 1–11

Rights & permissionsfor article Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts . Opens in a new window.
Research | 20 December 2019 | Open
Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors
- Kimio Yonesaka
- , Eiji Iwama
- , Hidetoshi Hayashi
- , Shinichiro Suzuki
- , Ryoji Kato
- , Satomi Watanabe
- , Takayuki Takahama
- , Junko Tanizaki
- , Kaoru Tanaka
- , Masayuki Takeda
- , Kazuko Sakai
- , Koichi Azuma
- , Yasutaka Chiba
- , Shinji Atagi
- , Kazuto Nishio
- , Isamu Okamoto
- & Kazuhiko Nakagawa
Scientific Reports 9 , 1–7

Rights & permissionsfor article Heregulin expression and its clinical implication for patients with <i>EGFR</i>-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors . Opens in a new window.
Research | 30 September 2019 | Open
Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI
- Kimio Yonesaka
- , Kaoru Tanaka
- , Mutsukazu Kitano
- , Hisato Kawakami
- , Hidetoshi Hayashi
- , Masayuki Takeda
- , Kazuko Sakai
- , Kazuto Nishio
- , Katsumi Doi
- & Kazuhiko Nakagawa
Oncogenesis 8 , 1–10

Rights & permissionsfor article Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI . Opens in a new window.
Research | 5 August 2019 | Open
A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing
- Kazuko Sakai
- , Masayuki Takeda
- , Shigeki Shimizu
- , Takayuki Takahama
- , Takeshi Yoshida
- , Satomi Watanabe
- , Tsutomu Iwasa
- , Kimio Yonesaka
- , Shinichiro Suzuki
- , Hidetoshi Hayashi
- , Hisato Kawakami
- , Yoshikane Nonagase
- , Kaoru Tanaka
- , Junji Tsurutani
- , Kazumasa Saigoh
- , Akihiko Ito
- , Tetsuya Mitsudomi
- , Kazuhiko Nakagawa
- & Kazuto Nishio
Scientific Reports 9 , 1–8

Rights & permissionsfor article A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing . Opens in a new window.
Research | 12 September 2018 | Open
A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L
- Tomonari Sasaki
- , Takashi Seto
- , Takeharu Yamanaka
- , Naonobu Kunitake
- , Junichi Shimizu
- , Takeshi Kodaira
- , Makoto Nishio
- , Takuyo Kozuka
- , Toshiaki Takahashi
- , Hideyuki Harada
- , Naruo Yoshimura
- , Shinichi Tsutsumi
- , Hiromoto Kitajima
- , Masaaki Kataoka
- , Yukito Ichinose
- , Kazuhiko Nakagawa
- , Yasumasa Nishimura
- , Nobuyuki Yamamoto
- & Yoichi Nakanishi
British Journal of Cancer 119 , 675–682

Rights & permissionsfor article A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L . Opens in a new window.
Research | 9 October 2018
An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC
- Kimio Yonesaka
- , Naoki Takegawa
- , Satomi Watanabe
- , Koji Haratani
- , Hisato Kawakami
- , Kazuko Sakai
- , Yasutaka Chiba
- , Naoyuki Maeda
- , Takashi Kagari
- , Kenji Hirotani
- , Kazuto Nishio
- & Kazuhiko Nakagawa
Oncogene 38 , 1398–1409

Rights & permissionsfor article An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC . Opens in a new window.

Search

Article Search

Advanced search

Quick links

Explore articles by subject
Find a job
Guide to authors
Editorial policies

nature.com sitemap

About us
Press releases
Press office
Contact us

Discover content

Journals A-Z
Articles by subject
Nano
Protocol Exchange
Nature Index

Publish with us

Guide to Authors
Guide to Referees
Editorial policies
Open access
Reprints & permissions

Researcher services

Research data
Language editing
Scientific editing
Nature Masterclasses
Nature Research Academies

Libraries & institutions

Librarian service & tools
Librarian portal
Open research
Recommend to library

Advertising & partnerships

Advertising
Partnerships & Services
Media kits
Branded content

Career development

Nature Careers
Nature Conferences
Nature events

Regional websites

Nature China
Nature India
Nature Japan
Nature Korea
Nature Middle East

Legal & Privacy

Privacy Policy
Use of cookies
Manage cookies/Do not sell my data
Legal notice
Accessibility statement
Terms & Conditions
California Privacy Statement

Refine your results by…

Filters ​

Filter By:

Nintedanib promotes antitumour immunity and shows antitumour activity in combination with PD-1 blockade in mice: potential role of cancer-associated fibroblasts

Heregulin expression and its clinical implication for patients with EGFR-mutant non-small cell lung cancer treated with EGFR-tyrosine kinase inhibitors

Aberrant HER3 ligand heregulin-expressing head and neck squamous cell carcinoma is resistant to anti-EGFR antibody cetuximab, but not second-generation EGFR-TKI

A comparative study of curated contents by knowledge-based curation system in cancer clinical sequencing

A randomised phase II trial of S-1 plus cisplatin versus vinorelbine plus cisplatin with concurrent thoracic radiotherapy for unresectable, locally advanced non-small cell lung cancer: WJOG5008L

An HER3-targeting antibody–drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC

Search

Quick links

Filters